Carriers of the UGT1A4 142T>G gene variant are predisposed to reduced olanzapine exposure—an impact similar to male gender or smoking in schizophrenic patients
- 472 Downloads
The impact of the UGT1A4, CYP1A2, and MDR1 genetic variants on olanzapine plasma levels, in relation to those of other individual factors, such as gender, smoking status, body weight, and age, was investigated in patients with schizophrenia.
A total of 121 patients were recruited from psychosis-specialized outpatient departments in Stockholm County. Olanzapine plasma concentrations were determined by high-performance liquid chromatography. Genotyping was carried out by PCR-restriction fragment length polymorphism or minisequencing, and haplotypes were analyzed using specialized computer software on population genetics. Multiple regression analysis was performed to investigate the combined effect of patient characteristics and genotypes/haplotypes on daily dose-corrected plasma concentrations of olanzapine.
In addition to , the results indicate that inter-patient differences in olanzapine exposure were explained by the known factor of time of sampling from last dose intake and by the following individual factors in order of relative impact: (1) male gender, (2) carrier of the UGT1A4 142T>G single nucleotide polymorphism (SNP), and (3) smoking. Each of these three factors predicted a decrease in daily dose-corrected plasma concentrations of 35, 25, and 21%, respectively. In contrast, age, body weight, and MDR1 or CYP1A2 haplotype did not have a significant impact.
At 12 h after dose intake, the regression model predicted a 5.1-fold higher olanzapine plasma level in a non-smoking female patient who did not carry the UGT1A4 142T>G SNP compared to a smoking man treated with the same dose but heterozygous for UGT1A4 142T>G SNP. Whether these combined genetic and environmental factors influence the risk of therapeutic failure remains to be established.
KeywordsAntipsychotics Drug metabolism Pharmacogenetics Polymorphism Therapeutic failure
The study was supported by the Swedish Research Council, Medicine (grants 3902 and 10909), by the Stockholm County Council (ALF grants 20060420, 20060100, and 20080022), and by grants from the Department of Drug Management and Informatics, Stockholm County Council, and Söderström-Königska Hospital. We thank Professor Martin Schalling for his important contribution in planning and setting up the study of metabolic risks in psychosis. We also thank Lili Milani for excellent assistance in the development of the CYP1A2 Minisequencing technique and Carina Schmidt for her highly qualified administration of patient samples. Drs. Sören Akselson, Deanne Mannelid, and Helena Ring are acknowledged for recruiting most of the patients.
- 12.University of Geneva (2000) Arlequin: a software for population genetics data analysis. Ver 2.000 (computer program). Genetics and Biometry Lab, Department of Anthropology, University of GenevaGoogle Scholar
- 13.Citrome L, Stauffer VL, Chen L, Kinon BJ, Kurtz DL, Jacobson JG et al (2009) Olanzapine plasma concentrations after treatment with 10, 20, and 40 mg/d in patients with schizophrenia: an analysis of correlations with efficacy, weight gain, and prolactin concentration. J Clin Psychopharmacol 29(3):278–283CrossRefPubMedGoogle Scholar
- 16.Nozawa M, Ohnuma T, Matsubara Y, Sakai Y, Hatano T, Hanzawa R et al (2008) The relationship between the response of clinical symptoms and plasma olanzapine concentration, based on pharmacogenetics: Juntendo University Schizophrenia Projects (JUSP). Ther Drug Monit 30(1):35–40CrossRefPubMedGoogle Scholar